Entropy Technologies LP Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Entropy Technologies LP acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 18,440 shares of the medical research company's stock, valued at approximately $3,624,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Empowered Funds LLC boosted its holdings in shares of IQVIA by 40.0% during the 4th quarter. Empowered Funds LLC now owns 4,813 shares of the medical research company's stock valued at $946,000 after purchasing an additional 1,376 shares during the last quarter. Generate Investment Management Ltd purchased a new stake in shares of IQVIA in the fourth quarter worth about $8,262,000. Graphene Investments SAS grew its holdings in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after buying an additional 2,700 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of IQVIA by 2.6% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,049,912 shares of the medical research company's stock worth $206,318,000 after acquiring an additional 26,648 shares in the last quarter. Finally, Silver Oak Securities Incorporated raised its holdings in shares of IQVIA by 18.0% during the 4th quarter. Silver Oak Securities Incorporated now owns 2,380 shares of the medical research company's stock worth $470,000 after acquiring an additional 363 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Bank of America cut their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Truist Financial restated a "buy" rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $251.67.

IQVIA Stock Down 1.6 %

IQV stock traded down $3.25 during trading on Wednesday, hitting $197.64. 1,044,006 shares of the company's stock traded hands, compared to its average volume of 1,411,836. The business has a fifty day simple moving average of $200.77 and a two-hundred day simple moving average of $218.81. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $35.87 billion, a P/E ratio of 26.35, a PEG ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.